Taiwan Liposome Company, Ltd. - ADRs (TLC): Price and Financial Metrics

Taiwan Liposome Company, Ltd. - ADRs (TLC)

Today's Latest Price: $4.43 USD

0.08 (1.84%)

Updated Nov 27 12:59pm

Add TLC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TLC Stock Summary

  • Taiwan Liposome Company Ltd's stock had its IPO on November 21, 2018, making it an older stock than only 4.34% of US equities in our set.
  • Revenue growth over the past 12 months for Taiwan Liposome Company Ltd comes in at 335.5%, a number that bests 97.9% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TLC comes in at -461.37% -- higher than that of just 0.99% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Taiwan Liposome Company Ltd, a group of peers worth examining would be AFMD, SPRO, GRTS, CBIO, and VCNX.
  • TLC's SEC filings can be seen here. And to visit Taiwan Liposome Company Ltd's official web site, go to www.tlcbio.com.

TLC Stock Price Chart Interactive Chart >

Price chart for TLC

TLC Price/Volume Stats

Current price $4.43 52-week high $12.65
Prev. close $4.35 52-week low $2.48
Day low $4.33 Volume 61,599
Day high $4.60 Avg. volume 102,764
50-day MA $4.60 Dividend yield N/A
200-day MA $4.86 Market Cap 164.34M

Taiwan Liposome Company, Ltd. - ADRs (TLC) Company Bio

Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.

TLC Latest News Stream

Event/Time News Detail
Loading, please wait...

TLC Latest Social Stream

Loading social stream, please wait...

View Full TLC Social Stream

Latest TLC News From Around the Web

Below are the latest news stories about Taiwan Liposome Company Ltd that investors may wish to consider to help them evaluate TLC as an investment opportunity.

Taiwan Liposome rockets 100% on planned trial of inhaled malaria drug for COVID-19

Thinly traded micro cap Taiwan Liposome (TLC) surges 100% premarket on increased volume in reaction to its submission of an Investigational New Drug ((IND)) Application to the Taiwan Food and Drug Administration seeking sign off on a clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension, an inhaled formulation of the malaria med, for the potential treatment...

Seeking Alpha | August 14, 2020

Taiwan Liposome EPS misses by $0.02, misses on revenue

Taiwan Liposome (TLC): Q2 GAAP EPS of -$0.11 misses by $0.02.Revenue of $0.4M (-42.7% Y/Y) misses by $0.19M.Press Release...

Seeking Alpha | August 5, 2020

Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan , July 15, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

Yahoo | July 15, 2020

TLC Announces Completion of US$23 Million Financing

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 30, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

Yahoo | June 30, 2020

TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy

Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours. TLC590 is a non-opioid, proprietary BioSeizer® sustained release formulation of ropivacaine.

Yahoo | May 31, 2020

Read More 'TLC' Stories Here

TLC Price Returns

1-mo -4.32%
3-mo -8.85%
6-mo -9.78%
1-year -12.80%
3-year N/A
5-year N/A
YTD -17.66%
2019 -2.18%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching TLC

Want to see what other sources are saying about Taiwan Liposome Company Ltd's financials and stock price? Try the links below:

Taiwan Liposome Company Ltd (TLC) Stock Price | Nasdaq
Taiwan Liposome Company Ltd (TLC) Stock Quote, History and News - Yahoo Finance
Taiwan Liposome Company Ltd (TLC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7784 seconds.